The Efficacy of Intravenous Immunoglobulin Therapy for Severe 2019-nCoV Infected Pneumonia
Status:
Not yet recruiting
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
In this single-center, randomized, open-label, controlled study, the investigators will
evaluate the efficacy and safety of Intravenous Immunoglobulin (IVIG) in combination with
standard care for severe 2019 novel coronavirus (2019-nCoV) pneumonia.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Tongji Hospital Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology